ArticleIndian journal of pharmacology
Evaluation of anti-inflammatory effect of anti-platelet agent-clopidogrel in experimentally induced inflammatory bowel disease.
Article in Indian journal of pharmacology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 33 citations in OpenAlex.
- Dietary Zinc Ameliorates TNBS-Induced Colitis in Mice Associated with Regulation of Th1/Th2/Th17 Balance and NF-κB/NLRP3 Signaling Pathway.Biological trace element research · 2024Article
- Maximizing Treatment Options for IBD through Drug Repurposing.Current pharmaceutical design · 2024Review
- Drug Repurposing in Crohn's Disease Using Danish Real-World Data.Pragmatic and observational research · 2024Article
- Venous Thromboembolism in Patients with Inflammatory Bowel Disease.Journal of clinical medicine · 2023Review
- Uncovering the shared molecule and mechanism between ulcerative colitis and atherosclerosis: an integrative genomic analysis.Frontiers in immunology · 2023Article
- 3,4-Methylenedioxy-β-Nitrostyrene Alleviates Dextran Sulfate Sodium-Induced Mouse Colitis by Inhibiting the NLRP3 Inflammasome.Frontiers in pharmacology · 2022Article
- Atherosclerotic cardiovascular disease in inflammatory bowel disease: The role of chronic inflammation.World journal of gastrointestinal pathophysiology · 2020Review
- Antiplatelet agents'-ticagrelol and eptifibatide-safety in experimental colitis in mice.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2020Article
- The Inflammatory Role of Platelets: Translational Insights from Experimental Studies of Autoimmune Disorders.International journal of molecular sciences · 2016Review
- Epidemiology, risk factors and management of cardiovascular diseases in IBD.Nature reviews. Gastroenterology & hepatology · 2015Review
- Animal models of inflammatory bowel disease: a review.Inflammopharmacology · 2014Review
- Multipotent role of platelets in inflammatory bowel diseases: a clinical approach.World journal of gastroenterology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo evaluate the anti-inflammatory effect of antiplatelet agent, clopidogrel, in experimentally induced inflammatory bowel disease (IBD). MATERIALS AND
methodsTNBS induced Crohn's disease model and oxazolone induced ulcerative colitis model were used to evaluate the role of clopidogrel in IBD. Spargue Dawley female and Wistar male rats were used respectively. The colitis was induced by a single intra-colonic application of TNBS (0.25 ml, 120 mg/ml in 50% ethanol) and oxazolone (450 μl 5% oxazolone in 50% ethanol). Rats were divided into four groups (n=6) in each model namely normal control, sham control, test and standard group. Drug treatment was carried out for 21 days. After 21 days, animals were sacrificed and evaluated for weight change, colon mucosal damage index (CMDI), disease activity Index (DAI) and myeloperoxidase (MPO) activity.
resultsResults showed that clopidogrel provided significant protection against mucosal damage in both the models of IBD. It significantly reduced (P<0.05) the decrease in body weight and CMDI, DAI and MPO scores.
conclusionThe results indicate that clopidogrel may be effective in treatment of Crohn's disease and ulcerative colitis. Platelet inhibition may be one of the mechanism for effectiveness of clopidogrel in the treatment of IBD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.